Elutable Surface Coating for Controlled Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional drug delivery techniques using medical devices, such as stents and catheters, face challenges in delivering bioactive agents effectively both short-term and long-term, and struggle with precise control over drug release, often leading to issues like clot formation and restenosis in blood vessels.
Innovation Solution
A medical device coating comprising a copolymer with hydrophilic and hydrophobic domains and a labile linker that can be cleaved by a controlled factor, allowing for controlled, localized release of bioactive agents, such as pharmaceuticals, directly to target locations within the body.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If conventional drug delivery techniques are used with medical devices, then devices can be introduced into body cavities, but blood vessel walls are disturbed or injured leading to clot formation and thrombosis
Solution Approach 1:
The coating is applied to the medical device before insertion into the body. The coating pre-establishes a protective barrier that prevents blood vessel wall injury and clot formation during device manipulation, addressing the harmful effects before they occur
Solution Approach 2:
The coating acts as an intermediary layer between the medical device and the blood vessel wall. This intermediate layer prevents direct contact and mechanical injury to the blood vessel, thereby preventing clot formation and thrombosis while allowing the device to function
2Reliability
If conventional drug delivery techniques are used, then devices can deliver bioactive agents, but precise control over delivery rate is difficult to achieve
Solution Approach 1:
The coating incorporates a labile linker that can be cleaved by a controlled factor, creating a dynamic system where the drug delivery rate can be adjusted by controlling the cleavage rate. This allows precise control over when and how quickly the bioactive agent is released
Solution Approach 2:
The system changes the chemical state of the drug-linker-coating complex by controlled cleavage of the labile linker. This parameter change (from intact to cleaved) triggers controlled drug release, enabling precise control over delivery timing and rate
3Reliability
If conventional drug delivery techniques are used, then devices can treat medical conditions, but effective delivery over both short term and long term is difficult
Solution Approach 1:
The coating is pre-applied to the device with the bioactive agent already incorporated. This preliminary preparation ensures that the drug is available for immediate release (short-term effectiveness) while the controlled degradation of the labile linker enables sustained release over longer periods
Solution Approach 2:
The coating system provides continuous drug delivery through the controlled cleavage and release mechanism. The labile linker degrades progressively, maintaining a continuous supply of bioactive agent to the target site throughout the required treatment duration, whether short-term or long-term
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables reliable and controlled delivery of therapeutic agents to specific body locations, reducing adverse reactions like clot formation and restenosis by releasing drugs only when needed, thereby improving treatment efficacy and safety.
Implementation Method 1
The copolymer comprises one or more hydrophilic domains and at least one hydrophobic domain
Implementation Method 2
labile linker is a linkage that can be cleaved by a controlled factor
Data Source
AI summary
Elutable coatings comprising protein resistant components and bioactive agent on medical devices are disclosed. The elutable coatings comprise labile linkers that can be cleaved under controlled conditions.